Overview

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.
Phase:
Phase 1
Details
Lead Sponsor:
Arrowhead Pharmaceuticals
Treatments:
Cetirizine
Diphenhydramine
Promethazine